This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Diabetes
  • /
  • Systematic review and meta-analysis of vildaglipti...
Journal

Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes.

Read time: 1 mins
Published:25th Mar 2020
Author: Bekiari E, Rizava C, Athanasiadou E, Papatheodorou K, Liakos A, Karagiannis T et al.
Ref.:Endocrine. 2015 Dec 29. [Epub ahead of print]
DOI:10.1007/s12020-015-0841-1

This systematic review and meta-analysis provides an update on the efficacy and safety of vildagliptin for treatment of type 2 diabetes mellitus (T2DM). We searched MEDLINE, COCHRANE, EMBASE and the drug manufacturer's website for randomised controlled trials of vildagliptin in patients with T2DM. Sixty-nine studies (28,006 patients) were included in the meta-analysis. Compared with placebo vildagliptin reduced HbA1c (weighted mean difference WMD -0.69 %; 95 % CI -0.83 to -0.56 %; I 2 = 82 %), and it was as effective as other antidiabetic agents (WMD -0.01 %; 95 % CI -0.16 to 0.14 %; I 2 = 93 %), without increasing the risk for hypoglycemia (OR 0.83; 95 % CI 0.59 to 1.16; I 2 = 0 % vs. placebo, and OR 0.19; 95 % CI 0.15 to 0.24; I 2 = 78 % versus active comparators). However, it was associated with an increase in the incidence of arthralgia compared with other comparators (OR 1.23; 95 % CI 1.02 to 1.48; I 2 = 0 %). On the contrary, vildagliptin did not increase the incidence of pancreatitis (OR 0.97; 95 % CI 0.37 to 2.53; I 2 = 0 %), serious adverse events (OR 0.98; 95 % CI 0.88 to 1.09; I 2 = 0 %) or death (OR 1.10, 95 % CI 0.75 to 1.61; I 2 = 0 %). Finally, odds ratio (OR) for heart failure, and overall cardiovascular and cerebrovascular events was 0.77 (95 % CI 0.46 to 1.30; I 2 = 0 %) and 0.91 (95 % CI 0.73 to 1.14; I 2 = 0 %), respectively. Vildagliptin is an effective and safe therapeutic option for patients with T2DM, both as monotherapy and as add-on treatment.

 

Read abstract on library site